PECTO

Informació principal

  • Denominació comercial:
  • PECTO TISANA EL NATURALISTA 20 bolsas filtro
  • formulario farmacéutico:
  • Filtros infusión
  • Vía de administración:
  • Oral
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • PECTO TISANA EL NATURALISTA 20 bolsas filtro
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 284232
  • última actualització:
  • 26-05-2018

Prospecte: composició, indicacions, interacció, posologia, embaràs, lactància, reaccions adverses

PECTO TISANA EL NATURALISTA 20 bolsas

filtro

altea+drosera+eucalipto+marrubio

Indicacions

Aliment que facilita l'expulsió de mocs des de les vies respiratòries (EXPECTORANT o MUCOLÍTIC).

Consideracions

Dipositeu el filtre en una tassa i afegiu-hi aigua bullint.

Deixeu reposar la infusió durant uns 5 minuts.

Podeu barrejar la infusió amb sucre, mel o algun edulcorant artificial per a millorar el seu gust

Pot prendre aquest medicament amb o sense aliments; si té molèsties d'estómac, prengui'l amb algun

aliment.

Segueixi estrictament la pauta indicada pel seu metge pel que fa a dosi i freqüència d'administració.

Mentre prengui aquest medicament procuri beure gran quantitat d'aigua i altres líquids, tret que el seu

metge li indiqui el contrari.

Efectes adversos

Si vostè segueix la pauta indicada, no solen aparèixer efectes adversos.

Posologia

Prengui 1 infusió en l'esmorzar, al dinar i al sopar.

VIA ORAL.

19-1-2019

Data sources on animal diseases: Country Card of Poland

Data sources on animal diseases: Country Card of Poland

Published on: Fri, 18 Jan 2019 Mapping the ‘data sources’ on animal diseases in each European Union (EU) Member State is one of the activities of EFSA's SIGMA1,2 project. The aim of this activity is to identify the central competent authorities responsible for managing the data on animal diseases and animal populations in each Member State. Initially EFSA is focusing on three diseases (on which EFSA is currently working): African swine fever, avian influenza and lumpy skin disease; and on the correspond...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-5-2018

Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall - Due to a Lack of Adequate Controls

Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall - Due to a Lack of Adequate Controls

Manufacturing products without proper process controls increases the probability that products will vary in strength, quality and purity

FDA - U.S. Food and Drug Administration

18-5-2018

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. is voluntarily recalling all lots of homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir, within expiry, to the consumer level. The drug products have been found to be manufactured with a lack of adequate controls.

FDA - U.S. Food and Drug Administration

23-1-2018

Overview of changes requiring an inspection in the GMP area

Overview of changes requiring an inspection in the GMP area

Companies that manufacture medicines must be authorised to perform manufacturing activities by the Danish Medicines Agency according to section 39 of the Danish Medicines Act. They must comply with the rules on good manufacturing practice (GMP) and will be inspected regularly by our GMP inspectors.

Danish Medicines Agency

8-9-2017

The Icelandic Medicines Agency advertises a vacancy for an inspector in its Inspection Unit

The Icelandic Medicines Agency advertises a vacancy for an inspector in its Inspection Unit

The Icelandic Medicines Agency advertises a vacancy for an inspector. The Agency is looking for a candidate who is willing and able to work on demanding and interesting tasks, including travels in Iceland and abroad on behalf of the Agency. The vacancy is a full post (100%).

IMA - Icelandic Medicines Agency

13-2-2017

New Q&A for clinical trial sponsors regarding contractual arrangements with vendors for electronic systems

New Q&A for clinical trial sponsors regarding contractual arrangements with vendors for electronic systems

The Good Clinical Practice (GCP) inspectors of the EU member states have published a new Q&A based on the pitfalls for sponsors to be aware of regarding contractual arrangements with vendors for electronic systems in connection with clinical trials.

Danish Medicines Agency

5-9-2016

Improved access to patient data in clinical trials for monitors and GCP inspectors

Improved access to patient data in clinical trials for monitors and GCP inspectors

The Danish Medicines Agency's inspectors have direct access to health information in patient records in all clinical trials on medicinal products notified from 1 July 2016.

Danish Medicines Agency

5-7-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).

Danish Medicines Agency

22-2-2019


Joint audit programme for European Economic Area good-manufacturing-practice inspectorates: Audit report template

Joint audit programme for European Economic Area good-manufacturing-practice inspectorates: Audit report template

Joint audit programme for European Economic Area good-manufacturing-practice inspectorates: Audit report template

Europe - EMA - European Medicines Agency

22-2-2019


Joint audit programme for EEA GMP inspectorates: Procedure for observing inspections

Joint audit programme for EEA GMP inspectorates: Procedure for observing inspections

Joint audit programme for EEA GMP inspectorates: Procedure for observing inspections

Europe - EMA - European Medicines Agency

22-2-2019


Joint audit programme for EEA GMP inspectorates: Procedure

Joint audit programme for EEA GMP inspectorates: Procedure

Joint audit programme for EEA GMP inspectorates: Procedure

Europe - EMA - European Medicines Agency

22-2-2019


Joint audit programme for EEA GMP inspectorates: Programme

Joint audit programme for EEA GMP inspectorates: Programme

Joint audit programme for EEA GMP inspectorates: Programme

Europe - EMA - European Medicines Agency

22-2-2019


Joint audit programme for EEA GMP inspectorates: Observed inspection checklist

Joint audit programme for EEA GMP inspectorates: Observed inspection checklist

Joint audit programme for EEA GMP inspectorates: Observed inspection checklist

Europe - EMA - European Medicines Agency